{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-002982","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2026-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.216913+00:00","generated_at":"2026-05-16T08:51:49.260090+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Abbott Q4 adj EPS $1.50 (+12% YoY); FY2025 revenue $44.3B; FY2026 adj EPS guide $5.55–$5.80","bullets":["Q4 GAAP EPS $1.01, adjusted EPS $1.50 (+12% YoY); revenue $11.46B (+4.4% reported, +3.8% ex-COVID).","FY2025 adjusted EPS $5.15 (+10% YoY); revenue $44.3B (+5.7% reported, +6.7% ex-COVID).","FY2026 guidance: organic sales growth 6.5%-7.5%; adjusted EPS $5.55-$5.80 (midpoint +10%).","Medical Devices sales +12.3% reported (+10.4% organic); CGM sales $2.0B up 15% reported.","Agreed to acquire Exact Sciences (cancer diagnostics); close expected Q2 2026. FDA OK for Volt PFA System."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-002982","json":"https://secwatch.observer/filing/0001628280-26-002982.json","markdown":"https://secwatch.observer/filing/0001628280-26-002982.md","text":"https://secwatch.observer/filing/0001628280-26-002982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000162828026002982/0001628280-26-002982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000162828026002982/abt-20260122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T08:51:49.260090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}